Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with lenvatinib and HAIC for unresectable intrahepatic cholangiocarcinoma
ChiCTR2500107397Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Shandong First Medical University. Primary endpoint: Objective Response Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimablenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500107397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107397.